**Question:** Which of the following is given to treat thrombocytopenia secondary' to anti-cancer therapy and is known to stimulate progenitor megakaryocytes?

A. Epoetin alfa (erythropoietin)
B. Thrombopoietin (TPO)
C. G-CSF (granulocyte colony-stimulating factor)
D. IL-6 (interleukin-6)

**Correct Answer:** B. Thrombopoietin (TPO)

**Core Concept:**
Thrombocytopenia is a condition characterized by low platelet count in the blood, which can be caused by various factors including anti-cancer therapy. Thrombopoietin (TPO), also known as erythropoietin-stimulating agent (ESA), is a hormone responsible for stimulating the production of megakaryocytes, which are precursors to platelets.

**Why the Correct Answer is Right:**
TPO is the correct answer because it is a hormone specifically responsible for stimulating megakaryocyte production, thereby increasing platelet count in patients with thrombocytopenia. Thrombopoietin acts on megakaryocytes and their precursors, promoting proliferation and differentiation, ultimately increasing platelet production in the bone marrow.

**Why Each Wrong Option is Incorrect:**

A. Epoetin alfa (erythropoietin): Erythropoietin primarily stimulates the production of red blood cells (erythrocytes) and not platelets.
B. IL-6 (interleukin-6): IL-6 is involved in the acute phase response and does not specifically target platelet production.
C. G-CSF (granulocyte colony-stimulating factor): G-CSF stimulates the production of neutrophils (granulocytes) and not platelets.
D. IL-11 (interleukin-11): IL-11 stimulates the production of osteoblasts and not platelets.

**Clinical Pearl:**
In clinical practice, understanding the appropriate therapy for thrombocytopenia is crucial as it helps in management of patients undergoing anti-cancer therapy. It ensures the preservation of platelet counts within the safe range to prevent bleeding complications and improve treatment outcomes.